Subcutaneous administration of amifostine (ethyol) is equivalent to intravenous administration in a rat mucositis model.

[1]  E. Maltezos,et al.  Down-regulation of intestinal-type alkaline phosphatase in the tumor vasculature and stroma provides a strong basis for explaining amifostine selectivity. , 2002, Seminars in oncology.

[2]  L. Shaw,et al.  New Dosing Regimens for Amifostine: A Pilot Study to Compare the Relative Bioavailability of Oral and Subcutaneous Administration with Intravenous Infusion , 2002, Journal of clinical pharmacology.

[3]  W. Curran,et al.  A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer. , 2001, Seminars in radiation oncology.

[4]  M. Hanson,et al.  Preclinical modeling of improved amifostine (Ethyol) use in radiation therapy. , 2002, Seminars in radiation oncology.

[5]  C. Spencer,et al.  Amifostine , 2012, Drugs.

[6]  D. Brizel,et al.  Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  P. U. Devi,et al.  Modification of radiation induced damage in mouse intestine by WR-2721. , 2000, Indian journal of experimental biology.

[8]  V. Georgoulias,et al.  Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Shaw,et al.  Measurement of both protein-bound and total S-2-(3-aminopropylamino)ethanethiol (WR-1065) in blood by high-performance liquid chromatography. , 2000, Journal of chromatography. B, Biomedical sciences and applications.

[10]  Y. Kataoka,et al.  Amifostine: Mechanisms of Action Underlying Cytoprotection and Chemoprevention , 2000, Drug metabolism and drug interactions.

[11]  R. Capizzi.  The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. , 1999, Seminars in oncology.

[12]  J. Glick,et al.  Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  L. Shaw,et al.  Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[14]  L. Milas,et al.  Protection by WR-3689 against gamma-ray-induced intestinal damage: comparative effect on clonogenic cell survival, mouse survival, and DNA damage. , 1989, Radiation research.

[15]  J. Glick,et al.  Final report of the phase I trial of single-dose WR-2721 [S-2-(3-aminopropylamino)ethylphosphorothioic acid]. , 1986, Cancer treatment reports.

[16]  H. Thames,et al.  Protection of acute and late radiation damage of the gastrointestinal tract by WR-2721. , 1986, International journal of radiation oncology, biology, physics.

[17]  G. Newton,et al.  Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721. , 1984, International journal of radiation oncology, biology, physics.

[18]  T. Morton,et al.  Radioprotection by WR-2721 of gamma-irradiated rat parotid gland: effect on gland weight and secretion at 8-10 days post irradiation. , 1984, International journal of radiation oncology, biology, physics.

[19]  K. Krohn,et al.  Radioprotection of normal tissues against gamma rays and cyclotron neutrons with WR-2721: LD50 studies and 35S-WR-2721 biodistribution. , 1984, Radiation research.

[20]  J F Fowler,et al.  A murine model of lip epidermal/mucosal reactions to X-irradiation. , 1983, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  J. Yuhas.  Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid. , 1980, Cancer research.

[22]  M. Davis,et al.  Radioprotection of the rat parotid gland by WR-2721: morphology at 60 days post-irradiation. , 1980, International journal of radiation oncology, biology, physics.

[23]  L. Brady,et al.  Radiation sensitizers, their use in the clinical management of cancer , 1980 .

[24]  J. Yuhas,et al.  The role of WR-2721 in radiotherapy and/or chemotherapy. , 1980, Cancer clinical trials.

[25]  A. D. Conger,et al.  Radioprotection by WR-2721 against long-term chronic damage to the rat parotid gland. , 1978, Radiation research.

[26]  A. D. Conger,et al.  Short-term radioprotective effects of WR-2721 on the rat parotid glands. , 1978, Radiation research.

[27]  J. Utley,et al.  Radioprotection of oral cavity structures by WR-2721. , 1978, International journal of radiation oncology, biology, physics.

[28]  J. Utley,et al.  Distribution of 35S-labeled WR-2721 in normal and malignant tissues of the mouse1,2. , 1976, Radiation research.

[29]  J. Yuhas.  Radiotherapy of experimental lung tumors in the presence and absence of a radioprotective drug, S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721). , 1973, Journal of the National Cancer Institute.

[30]  J. Yuhas.  Improvement of lung tumor radiotherapy through differential chemoprotection of normal and tumor tissue. , 1972, Journal of the National Cancer Institute.

[31]  J. Yuhas,et al.  Chemoprotection against three modes of radiation death in the mouse. , 1969, International journal of radiation biology and related studies in physics, chemistry, and medicine.